TIROFIBAN HYDROCHLORIDE (tir-o-fi'ban) Aggrastat Classifications: blood formers, coagulators, and anticoagulants; antiplatelet agent; glycoprotein iib/iiia receptor inhibitor Prototype: Abciximab Pregnancy Category: B |
250 mcg/mL, 50 mcg/mL injection
Antiplatelet agent that binds to the glycoprotein IIb/IIIa receptor of platelets.
Inhibits platelet aggregation. Effectiveness indicated by minimizing thrombotic events during treatment of acute coronary syndrome.
Acute coronary syndromes (unstable angina, MI).
Active internal bleeding within 30 d; acute pericarditis; aortic dissection; concurrent use with another glycoprotein IIb/IIIa receptor inhibitor (e.g., eptifibatide, abciximab); history of aneurysm or AV malformation; history of intracranial hemorrhage or neoplasm; hypersensitivity to tirofiban; major surgery or trauma within 3 d; stroke within 30 d; history of hemorrhagic stroke; thrombocytopenia following administration of tirofiban; pregnancy (category B); lactation.
Concomitant use with thrombolytic agents or drugs that cause hemolysis; hemorrhagic retinopathy; platelet count <150,000 mm3; severe renal insufficiency. Safety and efficacy in children <18 y are unknown.
Acute Coronary Syndromes Adult: IV Loading Dose 0.4 mcg/kg/min times 30 min IV Maintenance Dose 0.1 mcg/kg/min for 1224 h after angioplasty or arteriectomy Renal Impairment Clcr <30 mL/min: Reduce rate of infusion 50% |
Intravenous PREPARE: IV Infusion: Withdraw 100 mL from a 500-mL bag of NS or D5W and replace with 100 mL of tirofiban HCl injection. If a 250-mL IV bag is used, withdraw 50 mL of IV solution and replace with 50 mL of tirofiban injection. Either preparation yields 50 mcg/mL. Mix well before infusing. Note: Commercially premixed IV tirofiban solutions are available. ADMINISTER: IV Infusion: An initial loading dose of 0.4 mcg/kg/min for 30 min is usually followed by a maintenance infusion of 0.1 mcg/kg/min. INCOMPATIBILITIES Y-site: Diazepam. |
Assessment & Drug Effects
Patient & Family Education